Comparative Pharmacology
Head-to-head clinical analysis: AIRDUO RESPICLICK versus AZMACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIRDUO RESPICLICK versus AZMACORT.
AIRDUO RESPICLICK vs AZMACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone propionate (corticosteroid) and salmeterol (long-acting beta2-adrenergic agonist); fluticasone reduces inflammation via glucocorticoid receptor activation, salmeterol relaxes bronchial smooth muscle via beta2-receptor stimulation.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
Two inhalations (55 mcg/113 mcg per inhalation) twice daily via oral inhalation; maximum 2 inhalations twice daily. For patients with asthma, starting dose is one inhalation twice daily; may increase to two inhalations twice daily after 1-2 weeks if inadequate response.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
None Documented
None Documented
Salmeterol: terminal elimination half-life of 5.5 hours. Fluticasone furoate: terminal elimination half-life of approximately 24 hours, supporting once-daily dosing.
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Renal elimination of salmeterol: approximately 25% of dose excreted unchanged in urine. Fluticasone furoate: primarily excreted as metabolites in feces (≥90%) following intravenous administration, with less than 5% excreted in urine.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Category C
Category C
Inhaled Corticosteroid/LABA Combination
Inhaled Corticosteroid